Latest Period
Q2 2026
Security Snapshot
Immix Biopharma, Inc. - Common stock, $0.0001 par value (IMMX) Institutional Ownership
CUSIP: 45258H106
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
109
Shares (Excl. Options)
56,221,759
Price
$10.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock, $0.0001 par value
- Symbol
- IMMX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 56,221,759
- Total 13F value
- $579,553,830
- Portfolio coverage rank
- 0%
- Share change
- +24,153,494
- Value change
- +$249,367,754
- Number of holders
- 109
- Shares outstanding
- 69,482,482
- SEC-reported price per share
- $9.41
- Insider filing price
- $9.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IMMX - Immix Biopharma, Inc. - Common stock, $0.0001 par value is tracked under CUSIP 45258H106.
- 109 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 76 to 109 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $246,615,159 to $579,553,830.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 109 institutions filings for Q2 2026.
Security key
45258H106
Latest holder period
Q2 2026
13F holders
109
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
IMMX full holder history
Immix Biopharma, Inc. SEC filings
Immix Biopharma, Inc. company facts
Immix Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45258H106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
IMMX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Janus Henderson Group Ltd. | 14% | +7.7% | $96,168,777 | +$6,806,882 | 9,783,192 | +7.6% | JANUS HENDERSON GROUP Ltd. | 30 Jun 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | 5.6% | $38,248,717 | 3,891,019 | Eventide Asset Management, LLC | 30 Jun 2026 | |||
| Saturn V Capital Management LP | 7% | $17,987,759 | 3,693,585 | Saturn V Capital Management LP | 26 Dec 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 3.3% | -40% | $16,959,438 | -$10,291,071 | 1,750,200 | -38% | Millennium Management LLC | 31 Mar 2026 |
As of 30 Jun 2026, 109 institutional investors reported holding 56,221,759 shares of Immix Biopharma, Inc. - Common stock, $0.0001 par value (IMMX). This represents 81% of the company’s total 69,482,482 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
72%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 14% | 9,783,192 | 0% | 0.04% | $100,815,794 |
| Saturn V Capital Management LP | 6.7% | 4,658,429 | +26% | 6.9% | $48,028,403 |
| EVENTIDE ASSET MANAGEMENT, LLC | 5.6% | 3,891,019 | +53% | 0.54% | $40,116,406 |
| STATE STREET CORP | 4.3% | 2,996,935 | +1462% | 0% | $30,898,400 |
| BlackRock, Inc. | 4.3% | 2,989,972 | +538% | 0% | $30,826,610 |
| Deep Track Capital, LP | 4% | 2,775,000 | 0.42% | $28,610,250 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 2,507,122 | +40% | 0% | $25,848,428 |
| Opaleye Management Inc. | 3.4% | 2,345,000 | 2.2% | $24,176,950 | |
| MILLENNIUM MANAGEMENT LLC | 3% | 2,066,426 | +18% | 0.01% | $21,304,852 |
| UBS Group AG | 2.8% | 1,941,817 | +2427% | 0% | $20,020,133 |
| MARSHALL WACE, LLP | 2.6% | 1,794,908 | +9.3% | 0.02% | $18,505,502 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.5% | 1,739,919 | +319% | 0% | $17,939,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.1% | 1,473,409 | 0% | $15,190,847 | |
| GREAT POINT PARTNERS LLC | 1.8% | 1,277,642 | +265% | 3.1% | $13,172,489 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,201,097 | +159% | 0% | $12,387,152 |
| Velan Capital Investment Management LP | 1.6% | 1,085,000 | +47% | 6.9% | $11,186,350 |
| Bleichroeder LP | 1.4% | 1,000,000 | 0% | 1.8% | $10,310,000 |
| Logos Global Management LP | 1.4% | 1,000,000 | -18% | 0.44% | $10,310,000 |
| FRANKLIN RESOURCES INC | 1.4% | 969,120 | +0.01% | 0% | $9,991,627 |
| Burkehill Global Management, LP | 0.78% | 544,118 | +85% | 0.2% | $5,609,857 |
| AMERIPRISE FINANCIAL INC | 0.75% | 518,881 | 0% | $5,349,692 | |
| CITADEL ADVISORS LLC | 0.73% | 506,157 | +973% | 0% | $5,218,479 |
| Blue Owl Capital Holdings LP | 0.63% | 437,552 | -20% | 0.69% | $4,511,161 |
| NORTHERN TRUST CORP | 0.6% | 418,051 | +202% | 0% | $4,310,106 |
| Balyasny Asset Management L.P. | 0.6% | 417,227 | 0.01% | $4,301,610 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 56,221,759 | $579,553,830 | +$249,367,754 | $10.31 | 109 |
| 2026 Q1 | 27,077,219 | $246,615,159 | +$26,862,251 | $9.11 | 76 |
| 2025 Q4 | 24,382,712 | $127,497,003 | +$111,804,992 | $5.23 | 67 |
| 2025 Q3 | 2,765,928 | $5,781,309 | +$912,474 | $2.09 | 31 |
| 2025 Q2 | 2,262,228 | $4,682,595 | -$1,044,152 | $2.07 | 23 |
| 2025 Q1 | 2,918,442 | $4,902,496 | +$70,569 | $1.68 | 22 |
| 2024 Q4 | 2,870,949 | $6,315,600 | -$1,857,745 | $2.20 | 22 |
| 2024 Q3 | 4,094,667 | $6,102,781 | -$618,016 | $1.49 | 25 |
| 2024 Q2 | 4,429,414 | $8,774,511 | -$597,024 | $1.98 | 29 |
| 2024 Q1 | 5,090,000 | $15,715,858 | +$12,671,335 | $3.07 | 34 |
| 2023 Q4 | 783,068 | $5,326,329 | +$2,756,459 | $6.92 | 28 |
| 2023 Q3 | 405,051 | $1,385,659 | -$652,595 | $3.42 | 16 |
| 2023 Q2 | 633,819 | $1,705,059 | +$653,633 | $2.69 | 17 |
| 2023 Q1 | 400,796 | $729,846 | -$97,971 | $1.82 | 12 |
| 2022 Q4 | 440,750 | $1,011,250 | +$306,049 | $2.29 | 18 |
| 2022 Q3 | 298,959 | $406,000 | +$156,569 | $1.36 | 7 |
| 2022 Q2 | 183,385 | $475,000 | +$120,000 | $2.59 | 6 |
| 2022 Q1 | 146,485 | $352,000 | -$5,019,402 | $2.39 | 7 |
| 2021 Q4 | 1,538,439 | $5,473,200 | +$3,457,200 | $3.56 | 11 |